Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome [Yahoo! Finance]
Kyverna Therapeutics, Inc. (KYTX)
Company Research
Source: Yahoo! Finance
EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 am ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS). Conference Call Details Participants will need to register at the below-noted URL in order to listen and participate in the call. Once registered, participants will receive a dial-in phone number and unique PIN number which will be needed to join the call. The call can also be accessed via live webcast. The webcast and supporting presentation materials will be available on the "Events & Presentations" section of Kyverna's Investor Relations webpage at ir.kyvernatx.com . An archived replay will also be available on the website. Dial-In Reg
Show less
Read more
Impact Snapshot
Event Time:
KYTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYTX alerts
High impacting Kyverna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYTX
News
- Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies [Seeking Alpha]Seeking Alpha
- Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common StockGlobeNewswire
- Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
- Kyverna Therapeutics (NASDAQ:KYTX) was given a new $33.00 price target on by analysts at Morgan Stanley.MarketBeat
- Kyverna Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire
KYTX
Earnings
- 11/12/25 - Beat
KYTX
Sec Filings
- 12/22/25 - Form 4
- 12/22/25 - Form 4
- 12/18/25 - Form 8-K
- KYTX's page on the SEC website